What is Immunome's total equity?

Immunome (IMNM) reported total equity of $588.69M in Q1 2026.

How has Immunome's total equity changed year-over-year?

Immunome's total equity increased by 91.7% year-over-year, from $307.13M to $588.69M.

What is the long-term trend for Immunome's total equity?

Over 5 years (2020 to 2025), Immunome's total equity has grown at a 72.7% compound annual growth rate (CAGR), from $41.35M to $634.34M.

What does total equity mean?

Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.

Immunome IMNM Total Equity

Total Equity at other companies

PfizerPFE

$90.1B-0.3%

Arcus BiosciencesRCUS

$524M-1.3%

Nuvation BioNUVB

$319.56M-23.8%

SELLAS Life Sciences Group, Inc.SLS

$107.41M+287%

IDEAYA Biosciences, Inc.IDYA

$937.27M-8.5%

ImmunityBio, Inc.IBRX

-$870.01M-47.1%

Other financials

Income statement

See full

Revenue--100%

Operating income-$59.3M-32.9%

Net income-$53.8M-29.3%

EPS (diluted)-$0.48+7.7%

Balance sheet

See full

Cash & equivalents$582.7M+126%

Total debt$3.7M-22.6%

Total assets$619.8M+80.9%

Cash flow

See full

Operating cash flow-$58.6M-10.5%

CapEx$3.0M-18.1%

Free cash flow-$61.6M-8.7%

Valuation

See full

Market cap$2.19B+323%

Enterprise value$1.61B+470%

P/S545.2×+498×

Profitability

See full

Operating margin-5,947.9%-12,002pp

Net margin-5,593.8%-11,284pp

FCF margin-5,118.9%-8,601pp

Returns & leverage

See full

Return on equity-50.1%-10.8pp

Debt / equity0×0.0×

Current ratio21.7×+11.2×

Where this comes from

Reported directly by Immunome in its filing.

Tagged under the XBRL concept us-gaap:StockholdersEquity.

The official record: Immunome’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Immunome's total equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Immunome's total equity?: Immunome (IMNM) reported total equity of $588.69M in Q1 2026.
How has Immunome's total equity changed year-over-year?: Immunome's total equity increased by 91.7% year-over-year, from $307.13M to $588.69M.
What is the long-term trend for Immunome's total equity?: Over 5 years (2020 to 2025), Immunome's total equity has grown at a 72.7% compound annual growth rate (CAGR), from $41.35M to $634.34M.
What does total equity mean?: Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.